BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Herranz Benito, Daniel

eRA COMMONS USER NAME (credential, e.g., agency login): DHBENITO

POSITION TITLE: Assistant Professor of Pharmacology, Rutgers Cancer Institute of New Jersey

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	Completion Date MM/YYYY	FIELD OF STUDY
Complutense University, Madrid, Spain	PharmD	09/2005	Pharmacy
Autonomous University of Madrid (UAM) and Spanish National Cancer Centre (CNIO), Spain	PhD	12/2011	Biochemistry and Molecular Biology
Columbia University, New York, NY	Postdoc Fellow	06/2015	Research on T-ALL (Adolfo Ferrando's Lab)
Columbia University, New York, NY	Assoc. Res. Scientist	06/2017	Research on T-ALL (Adolfo Ferrando's Lab)

A. Personal Statement

I am a translational scientist with combined training in metabolism, epigenetics, and how both affect human cancer through the generation and analysis of relevant mouse models. During my PhD, guided by Dr. Manuel Serrano at the Spanish National Cancer Center (CNIO), I focused on the molecular and genetic characterization of Sirt1 in metabolism and cancer. My results led to the publication of four first author papers in *Nature Communications*, *PNAS*, *Oncogene* and *Cell Cycle*, a highly cited review paper in *Nature Reviews Cancer* and, more recently, a corresponding-author paper in *EMBO Reports* (described in section c). For my postdoctoral training, I joined the laboratory of Dr. Adolfo Ferrando at Columbia University, where I led a highly pioneering study on NOTCH1-bound enhancers resulting in the identification of N-Me, a key long-range oncogenic enhancer controlling *MYC* expression in NOTCH1-induced leukemia, which was published in *Nature Medicine* (described in section c). In addition, I also dissected the role of cancer metabolism in NOTCH1-induced transformation and resistance to anti-NOTCH1 therapies, leading to another first-author study in *Nature Medicine* (1). These studies unveiled critical aspects of the anti-NOTCH therapeutic response and revealed new targets for T-ALL treatment.

After finishing my training at Columbia University, I started my independent laboratory at Rutgers Cancer Institute in July 2017. In these 5 years, I have established a highly successful and productive independent laboratory, as reflected by the different funding sources obtained (described below), as well as by the publication of: (**i**) a corresponding author paper in *Blood Cancer Discovery*, in which we describe and dissect a novel enhancer regulatory region of *PTEN* (2); (**ii**) a corresponding author paper in *Leukemia*, in which we describe the antileukemic effects of a novel Serine hydroxymethyl transferase inhibitor *in vivo* (described in section c); (**iii**) a corresponding author paper in *Blood*, describing the highly antileukemic effect of a novel mitochondrial uncoupling drug in T-ALL *in vivo* (3); (**iv**) a corresponding author paper in *Blood Cancer Discovery*, in which we describe and dissect a NOTCH1-SIRT1-KAT7 axis (4); and (**v**) a corresponding author review paper on the enhancer landscape of MYC, published in *Trends in Cancer* (described in section c).

My scientific productivity (30 peer-reviewed publications -including 5 corresponding author studies- and 8 reviews/previews) together with my background in NOTCH1 signaling and transformation, leukemia animal models, metabolic reprogramming in cancer, as well as the unique tools that I already have available in my laboratory (conditional knockout T-ALLs for several critical metabolic regulators) make me exceptionally well-suited to establish and maintain a successful independent research laboratory.

Current support in my lab that I would like to highlight include:

Leukemia & Lymphoma Society (LLS) Scholar Award 1386-23 Herranz (PI) 07/01/22-06/30/27
Therapeutic exploitation of novel mouse models and metabolic interventions in leukemia

Rutgers Committee to Expedite Translational Initiatives (CETI) Award	Herranz (PI)	02/15/22-02/14/23
Dissecting the antileukemic potential of IRS-17		
Ludwig (Princeton Branch) grant	Herranz (PI)	01/01/22-12/31/23
Differential effects between IRS-17 and methotrexate in leukemia		
Alex's Million Mile Grant (ALSF*)*	Herranz (PI)	01/04/22-01/03/23
Dissecting the antileukemic potential of a novel dual metabolic inhibitor		
Ludwig (Princeton Branch) grant	Herranz (PI)	01/01/21-12/31/23
Comprehensive investigation of therapeutic dietary interventions in leukemia in vivo		
133916-RSG-19-161-01-TBE (ACS)	Herranz (PI)	01/01/20-12/31/23
The role of SIRT1 in T-Cell Acute Lymphoblastic Leukemia		
R01 CA236936 (NIH/NCI)	Herranz (PI)	07/01/19-06/30/24
The role of glutaminolysis as a therapeutic target in T-ALL		

1. **Herranz, D**., Ambesi-Impiombato, A., Sudderth, J., Sánchez-Martín, M., Belver, L., Tosello, V., Xu, L., Wendorff, AA., Castillo, M., Haydu, JE., Márquez, J., Matés, JM., Kung, AW., Rayport, S., Cordon-Cardo, C., DeBerardinis RJ. and Ferrando, AA. (2015). Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in acute lymphoblastic leukemia. **Nat Med**, 21: 1182-1189. (PMID: 26390244) (PMCID: PMC4598309)
2. Tottone, L. , Lancho, O., Loh, JW., Singh, A., Kimura, S., Roels, J., Kuchmiy, A., Strubbe, S., Lawlor, MA., da Silva-Diz, V., Luo, S., Gachet, S., Garcia-Prieto, CA., Hagelaar, R, Esteller, M., Meijerink, JPP., Soulier, J., Taghon, T., Van Vlierberghe, P., Mullighan, CG., Khiabanian, H., Rocha, PP. and **Herranz, D.*** (2021) A Tumor Suppressor Enhancer of PTEN in T-cell development and leukemia. **Blood Cancer Discov**, 2, 92-109. (PMID: 33458694) (PMCID: PMC7810363) (HerranzLab members; ***corresponding authorship)**
Highlighted *in a comment in the same issue:* ***Blood Cancer Discov 2021;2:1-2****.*
3. da Silva-Diz, V.*, Cao, B., Lancho, O., Chiles, E., Alasadi, A., Aleksandrova, M., Luo, S., Singh, A., Tao, H., Augeri, D., Minuzzo, S., Indraccolo, S., Khiabanian, H., Su, X., Jin, S.*, and **Herranz, D.*** (2021) A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia. **Blood**, 138, 1317-1330. (PMID: 33876224) (HerranzLab members; ***corresponding authorship**).
4. Lancho, O., Singh, A., da Silva-Diz, V., Aleksandrova, M., Khatun, J., Tottone, L., Renck Nunes, P., Luo, S., Zhao, C., Zheng, H., Chiles, E., Zuo, Z., Rocha, PP., Su, X., Khiabanian, H., and **Herranz, D.*** (2023) A therapeutically targetable NOTCH1-SIRT1-KAT7 axis in T-cell Leukemia. **Blood Cancer Discov**, 4, 12-33 (PMID: 36322781) (PMCID: PMC9818047) (HerranzLab members; ***corresponding authorship**)
Highlighted *in a comment in the same issue:* ***Blood Cancer Discov 2023;4:1****.*

B. Positions and Honors

Positions

2022-	Assistant Professor of Pediatrics, Rutgers University, New Brunswick, NJ
2018-	Voluntary Scientific Board Member for Molecular Medicine PhD, Sapienza University, Rome(Italy)
2017-	Assistant Professor of Pharmacology, Rutgers University, New Brunswick, NJ
2015 - 2017	Associate Research Scientist, Columbia University, New York, NY
2011 - 2015	Postdoctoral researcher, Columbia University, New York, NY
2005 - 2011	Predoctoral student, Spanish National Cancer Centre (CNIO), Madrid, Spain

Other Experience and Professional Memberships

2022-	*Rally! Foundation*, Medical Advisory Board
2020-	Member of Journal Editorial Boards: (i) *Translational Oncology*; (ii) *Oncogene*
2016-	Active Member, American Society of Hematology (ASH), Member # 1296534
2012-	Active Member, American Association for Cancer Research (AACR), Member # 250877

Reviewer Experience

2021-	Review College Member for FWO (Research Foundation-Flanders, Belgium), panels 2021-2023
2021-	Reviewer for 63rd ASH Annual Meeting and Coordinating Reviewer for 64th Annual meeting
2018-	*Ad Hoc* reviewer for Foundation grants: *Bloodwise/CRUK* (UK; 2018, 2019, 2022); *FWO* (Belgium; 2018); *ISF* (Israel Science Foundation; 2019, 2020); *TV3 Marató on Cancer* (Spain, 2019); *Alex's Lemonade Stand Foundation (ALSF) Innovation Grants* (USA; 2022); *Leukemia & Lymphoma Society (LLS) Blood Cancer Discovery Grants* (USA; 2022); *Barts Charity* (UK, 2022); *Foundation for Innovation's Grants* (Canada; 2022); *New Frontiers in Research Fund* (Canada; 2022)

2017- Reviewer for six different NIH/NCI study sections:
2018/01 ZCA1 SRB-P (J1) S meeting; 2018/10 ZCA1 SRB-P (O1) S meeting; 2019/05 ZCA1 SRB-P (M2) S meeting; 2019/10 ZCA1 SRB-P (O1) S meeting; 2020/05 ZCA1 SRB-P (M1) S meeting; 2023/02 Basic Mechanisms in Cancer Health Disparity Study Section.

2011- *Ad Hoc* reviewer for journals: *Nature Medicine, Cancer Discovery, Blood Cancer Discovery, Science Translational Medicine, Science Advances, Nature Cancer, Blood, Blood Advances*, *Nature Communications*, *Journal of Experimental Medicine, Journal of Clinical Investigation, EMBO Molecular Medicine*, *Leukemia*, *Cancer Research, Clinical Cancer Research, Aging Cell, Haematologica*, *Oncogene, iScience*, *Journal of Molecular Medicine*, *PloS ONE, EBioMedicine, etc.*

Invited Seminars

1. 10/12/23: The University of Alabama at Birmingham, AL (USA)
2. 05/23/23: Icahn School of Medicine at Mt. Sinai, NY (USA)
3. 04/15/23: 2023 AACR Annual Meeting, Orlando, FL (USA)
4. 02/01/23: MD Anderson Cancer Centre, Houston, TX (USA)
5. 03/15/21: Josep Carreras Leukaemia Research Institute (IJC), Barcelona (Spain)
6. 10/08/19: Memorial Sloan Kettering Cancer Center, NY (USA)
7. 09/24/19: Hackensack Meridian Health Center for Discovery & Innovation, Nutley, NJ (USA)
8. 06/17/19: National Cancer Institute (NCI), Bethesda, MD (USA)
9. 06/04/18: Spanish National Cancer Center (CNIO), Madrid (Spain)
10. 12/20/17: IMDEA Food Institute, Madrid (Spain)
11. 12/18/17: Institut de Recherche en Cancérologie de Montpellier, INSERM (France)
12. 01/23/17: Sanford Burnham Prebys Medical Discovery Institute, San Diego, CA (USA)
13. 12/09/16: Nationwide Children's Hospital, Columbus, OH (USA)
14. 09/12/16: Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (USA)
15. 09/05/16: Northwestern University, Chicago, IL (USA)
16. 07/29/16: Children's Hospital of Philadelphia, CHOP-UPenn, Philadelphia, PA (USA)
17. 06/23/16: University of Florida Cancer Center, Gainesville, FL (USA)

Oral Presentations at International Meetings

1. AACR Annual Meeting NextGen Star presentation (2022)
2. AACR Annual Meeting, held virtually due to coronavirus pandemic (2020)
3. AACR Special Conference on Metabolism & Cancer, Brooklyn, NY, USA (2018)
4. Cancer as an Evolving and Systemic Disease, Nature Conference, MSKCC, NY, USA (2016)
5. ASH Annual Meeting, San Francisco, CA, USA (2014)
6. AACR Annual Meeting, San Diego, CA, USA (2014)
7. ASH Annual Meeting, Atlanta, GA, USA (2012)
8. Idibell Cancer Conference (ICC) on Sirtuins, Barcelona, Spain (2009)
9. Mechanisms & Models of Cancer, Salk Institute, San Diego, CA (2009)
10. Molecular Genetics of Aging, Cold Spring Harbor Laboratory, NY (2008)

Honors

2022-2027	Leukemia & Lymphoma Society Scholar
2022	AACR NextGen Star
2021	Recognized as a world expert (top 0.1%) in T-ALL by Expertscape
2019-2020	Interstellar Initiative Awardee (NYAS-AMED)
2017-2018	Alex's Lemonade Shark Tank Award
2017	EHA-ASH TRTH Award (EHA-ASH Translational Research Training in Hematology)
2015*	Leukemia & Lymphoma Society Special Fellow* (declined due to incompatibility with K99/R00)*
2015-2017	Alex's Lemonade Young Investigator Award
2015-2020	K99/R00 Pathway to Independence Career Development Award NIH/NCI
2014	ASH Abstract Achievement Award, 56th ASH Annual Meeting
2012	ASH Abstract Achievement Award, 54th ASH Annual Meeting
2012-2015	Leukemia & Lymphoma Society Fellow
2011	Mutua Madrileña Foundation Best 2010 Paper Prize (Herranz, D., *et al*. Nat Commun. 2010)
2011	St. Nicholas Foundation Award to the Best Thesis by the Spanish Royal Academy of Medicine
2011	Autonomous University of Madrid Extraordinary Doctorate Prize
2005-2011	Eduardo Gallego Fellowship granted by the "Francisco Cobos Foundation"

2005-2011 Predoctoral fellowship from the Spanish Ministry of Health (FIS)
2005 First runner-up Spanish National Prize in Pharmacy
2005 Complutense University Extraordinary Prize in Health Sciences Field
2005 Complutense University Extraordinary Prize in Pharmacy

C. Contributions to Science

1. **Sirt1 role in cancer, metabolism and aging:** My PhD thesis directly addressed the role of Sirt1 in cancer, metabolism and aging. To unveil Sirt1 functions, I generated novel mouse models overexpressing *Sirt1* under its own endogenous regulation. These mice were instrumental to show that Sirt1 protects against high-fat diet metabolic damage, and that Sirt1 improves healthspan without affecting lifespan. Moreover, I was the first to show Sirt1 can act *in vivo* both as a tumor suppressor (obesity-promoted liver cancer) or oncogene (thyroid cancer driven by *Pten* loss). I also published a co-corresponding *EMBO reports* paper describing Sirt1's protective role from K-Ras driven lung cancer. Follow-up studies on Sirt1 in T-ALL constitute the basis for my American Cancer Society (ACS) grant, which have led to a recent corresponding *Blood Cancer Discovery* paper describing Sirt1 oncogenic role in T-ALL via deacetylation of KAT7. Overall, I contributed to 16 publications (including 4 first-author papers, 2 corresponding-author papers and 1 highly cited first-author *Nature Reviews Cancer*), which constitute a cornerstone in the field of Sirt1.
   a. Pfluger, P.T.[#], **Herranz, D.[#],** Velasco-Miguel, S.[#], Serrano, M. and Tschöp, M.H. (2008). Sirt1 protects against high-fat diet-induced metabolic damage. **Proc Natl Acad Sci USA**, 105,9793-8. (PMID: 18599449) (PMCID: PMC2474520) **([#]Co-first authorship)**
   b. **Herranz, D**., Muñoz-Martin, M., Cañamero, M., Mulero, F., Martinez-Pastor, B., Fernandez-Capetillo, O., and Serrano, M. (2010). Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. **Nat Commun**, 1:3. (PMID: 20975665) (PMCID: PMC3641391)
   c. Costa-Machado, LF., Martin-Hernandez, R., Sanchez, MA., Hess, K., Vales-Villamarin, C., Barradas, M., Lynch, C., de la Nava, D., Cañamero, M., Martinez, L., Sanchez-Carbayo, M., **Herranz, D.***, Serrano, M.* and Fernandez-Marcos, PJ.* Sirt1 protects from K-Ras-driven lung carcinogenesis. (2018) **EMBO Rep**, 19(9); pii: e43879. (PMID: 30021836) (PMCID: PMC6123659) **(*Co-corresponding authorship)**
   d. Lancho, O., Singh, A., da Silva-Diz, V., Aleksandrova, M., Khatun, J., Tottone, L., Renck Nunes, P., Luo, S., Zhao, C., Zheng, H., Chiles, E., Zuo, Z., Rocha, PP., Su, X., Khiabanian, H., and **Herranz, D.*** (2022) A therapeutically targetable NOTCH1-SIRT1-KAT7 axis in T-cell Leukemia. **Blood Cancer Discov** (PMID: 36322781; *in press*) (Herranz Lab members; ***corresponding authorship**)

2. **NOTCH1 enhancer-driven expression of MYC in hematological malignancies:** During the last 10 years, I have strongly focused on dissecting the complex transcriptional program controlled by NOTCH1. Using an integrated analysis of human and mouse NOTCH1 ChIP-seq, chromosome conformation capture and reporter assays, I discovered a **N**OTCH1-bound **M**yc **e**nhancer (N-Me) as the long-sought missing link in the regulation of *MYC* by NOTCH1 in T-cells. To characterize N-Me functions *in vivo*, I generated N-Me knockout and conditional knockout mouse models, which showed that N-Me is critically required for the normal development of T-cells, as well as for the generation and maintenance of NOTCH1-induced T-ALL. Finally, I uncovered recurrent duplications of N-Me in 5% of human T-ALL cases, highlighting its importance in this disease. The relevance of this study was highlighted in two comments in *Nature Medicine* (PMID: 25295936) and *Cancer Discovery* (PMID: 25367958). Moreover, I also contributed to a subsequent study where we described NOTCH1-controlled enhancers of *MYC* in CLL, as well as a recent corresponding-author review paper on the *MYC* enhancer-ome. Finally, the follow-up of these innovative studies led to a paper recently published in *Cancer Discovery* uncovering a dominant role for Gata3 in the activation of N-Me.
   a. **Herranz, D.**, Ambesi-Impiombato, A., Palomero, T., Schnell, SA., Belver, L., Wendorff, AA., Xu, L., Castillo-Martin, M., Llobet-Navás, D., Cordon-Cardo, C., Clappier, E., Soulier, J., and Ferrando, AA. (2014). A NOTCH1-driven MYC enhancer promotes T-cell development, transformation and acute lymphoblastic leukemia. **Nat Med**, 20: 1130-1137. (PMID: 25194570) (PMCID: PMC4192073)
   b. Fabbri, G., Holmes, A., Viganotti, M., Scuoppo, C., Belver, L., **Herranz, D.**, Yan, XJ., Kieso, Y., Rossi, D., Gaidano, G., Chiorazzi, N., Ferrando, AA., and Dalla-Favera, R. (2017) Common non-mutational NOTCH1 activation in Chronic Lymphocytic Leukemia. **Proc Natl Acad Sci USA**, 114, E29110-E2919. (PMID: 28314854) (PMCID: PMC5389283)
   c. Lancho, O., **Herranz, D.*** (2018). The MYC enhancer-ome: long-range transcriptional regulation of MYC. **Trends Cancer**, 4, 810-822. (PMID: 30470303) (PMCID: PMC6260942) **(*Corresponding authorship)**
   d. Belver, L., Yang, AY., Alberto, R., **Herranz, D.**, Brundu, FG., Quinn, SA., Perez-Duran, P., Alvarez, S., Gianni, F., Rashkovan, M., Gurung, D., Rocha, PP., Raviram, R., Reglero, C., Cortes, JR., Cooke, A., Wendorff, A., Cordo, V., Meijerink, J., Rabadan, R. and Ferrando, AA. (2019). Gata3-controlled

nucleosome eviction drives Myc enhancer activity in T-cell development and leukemia. **Cancer Discov**, 9, 1774-1791. (PMID: 31519704) (PMCID: PMC6891196)

3. **Enhancer-driven expression of Tumor Suppressor Genes (TSGs):** As an independent investigator, one of my main research interests focuses on the discovery and dissection of enhancer regions controlling the expression of TSGs, which remains a largely unexplored area of research. In this context, we have very recently uncovered a previously unknown enhancer of *PTEN* (PE) in normal T-cell development and transformation. Mice lacking PE show drastically reduced levels of PTEN in T-cells, and develop NOTCH1-induced leukemias with faster kinetics. In addition, secondary loss of PE in established leukemias leads to accelerated progression and a gene expression signature driven by PTEN loss. Finally, we uncovered recurrent deletions encompassing PE in human T-ALL cases, which correlated with decreased levels of *PTEN*, overall underscoring a novel mechanism of regulation of *PTEN*, which is relevant for leukemogenesis. These important results were recently published in a corresponding-author paper in *Blood Cancer Discovery*.
   a. Tottone, L. , Lancho, O., Loh, JW., Singh, A., Kimura, S., Roels, J., Kuchmiy, A., Strubbe, S., Lawlor, MA., da Silva-Diz, V., Luo, S., Gachet, S., Garcia-Prieto, CA., Hagelaar, R, Esteller, M., Meijerink, JPP., Soulier, J., Taghon, T., Van Vlierberghe, P., Mullighan, CG., Khiabanian, H., Rocha, PP. and **Herranz, D.*** (2021) A Tumor Suppressor Enhancer of PTEN in T-cell development and leukemia. **Blood Cancer Discov** 2, 92-109 (PMCID: PMC7810363) (HerranzLab members; ***corresponding authorship)**

4. **Therapeutically targetable metabolic vulnerabilities in T-ALL:** The role of cancer metabolism in T-ALL has been my other major focus in the last 10 years. Using a combination of gene expression, metabolomic, ^{13}C-labeling experiments and state-of-the-art experimental therapeutics, I uncovered a critical role for the metabolic effects of NOTCH1 inhibition in the antileukemic activity of anti-NOTCH1 therapies. The relevance of this study was highlighted in two comments in *Cell Metabolism* (PMID:26536486) and *Cancer Discovery* (PMID:26428986). The follow-up of these studies constitutes the basis for my currently funded R01 grant. In my independent laboratory, we described the first inhibitor of serine hydroxymethyltransferase (SHMT) with target engagement *in vivo*. In this joint *Leukemia* paper with the Rabinowitz Lab, we showed highly antileukemic effects for SHMT inhibition in mouse primary T-ALL and human T-ALL PDXs. Moreover, SHMT inhibition shows therapeutic activity in methotrexate-resistant cells, thus uncovering a novel strategy to treat T-ALL, which was selected as a 2020 highlight by the NCI. We also recently dissected the antileukemic effects of a novel mitochondrial uncoupler (MB1-47). MB1-47 led to highly antileukemic effects in mouse T-ALL and human T-ALL PDXs, demonstrating OxPhos critical role in T-ALL. These therapeutically relevant results were recently published in *Blood*. Finally, our collaborative efforts with the Rabinowitz Lab led to exciting results just accepted for publication in *Nature* demonstrating that, unlike leukemias, solid tumors show slow TCA flux *in vivo* and, even if hyperglycolytic, make ATP at an overall slower than normal rate.
   a. **Herranz, D**., Ambesi-Impiombato, A., Sudderth, J., Sánchez-Martín, M., Belver, L., Tosello, V., Xu, L., Wendorff, AA., Castillo, M., Haydu, JE., Márquez, J., Matés, JM., Kung, AW., Rayport, S., Cordon-Cardo, C., DeBerardinis RJ. and Ferrando, AA. (2015). Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in acute lymphoblastic leukemia. **Nat Med**, 21: 1182-1189. (PMID: 26390244)
   b. Garcia-Canaveras, JL.[#], Lancho, O.[#], Ducker, GS., Ghergurovich, JM, Xu, X., da Silva-Diz, V., Kim, H., **Herranz, D.*** and Rabinowitz, JD.* (2021) SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia. **Leukemia**, 35, 377-388. (PMID: 32382081) (PMCID: PMC7647950) ([#]co-first authorship; HerranzLab members; ***co-corresponding authorship**)
   ***Selected** as a **2020 highlight** by the **NCI** as per @NCICancerBio, NCI Division of Cancer Biology official Twitter account, on Dec 24th 2020; link to tweet not provided in order to comply with NOT-OD-20-174)*
   c. da Silva-Diz, V.*, Cao, B., Lancho, O., Chiles, E., Alasadi, A., Aleksandrova, M., Luo, S., Singh, A., Tao, H., Augeri, D., Minuzzo, S., Indraccolo, S., Khiabanian, H., Su, X., Jin, S.*, and **Herranz, D.*** (2021) A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia. **Blood**, 138, 1317-1330. (PMID: 33876224) (HerranzLab members; ***corresponding authorship**).
   d. Bartman, C.R., Weilandt, D.R., Shen, Y., Dong Lee, W., Han, Y., TeSlaa, T., Jankowski, C.S.R., Samarah, L., Park, N.R., da Silva-Diz, V., Aleksandrova, M., Gultekin, Y., Marishta, A., Wang, L., Yang, L., Roichman, A., Bhatt, V., Lan, T., Hu, Z., Xing, X., Lu, W., Davidson, S., Wühr, M., Vander Heiden, M.G., **Herranz, D.**, Guo, J.Y., Kang, Y., and Rabinowitz J.D. (2023) Slow TCA flux and ATP production in primary solid tumours but not metastasis. **Nature**, *in press*. (PMID: 36725930) (HerranzLab members)

Complete List of Published Work in MyBibliography - 38 publications (h index= 24):
https://www.ncbi.nlm.nih.gov/myncbi/18QGgz-Kd8MITT/bibliography/public/